Forest Laboratories, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company.
Features:
- Detailed information on Forest Laboratories, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Forest Laboratories, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Forest Laboratories, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Forest Laboratories, Inc.
- Intelligence on Forest Laboratories, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Forest Laboratories, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Forest Laboratories, Inc. (Forest Labs or 'the company') is a specialty pharmaceutical company engaged in the development, manufacture and sales of both branded and generic forms of ethical drug products and other healthcare products. It primarily focuses in the therapeutic areas of central nervous systems and cardiovascular. The company primarily operates in the US, where it is headquartered in New York City, New York. Forest Labs employed about 5,700 people as of March 31, 2012. The company recorded total net sales of $4,392.5 million during the financial year ended March 2012 (FY2012), an increase of 4.3% over FY2011. The operating profit* of the company was $1,217.3 million in FY2012, a decrease of 6.9% over FY2011. The net profit was $979.1 million in FY2012, a decrease of 6.5% over FY2011. *Earnings before interest and taxes.
Reasons to Purchase:
- Gain understanding of Forest Laboratories, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Forest Laboratories, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Forest Laboratories, Inc.’s business structure, strategy and prospects
Features:
- Detailed information on Forest Laboratories, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Forest Laboratories, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Forest Laboratories, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Forest Laboratories, Inc.
- Intelligence on Forest Laboratories, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Forest Laboratories, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Forest Laboratories, Inc. (Forest Labs or 'the company') is a specialty pharmaceutical company engaged in the development, manufacture and sales of both branded and generic forms of ethical drug products and other healthcare products. It primarily focuses in the therapeutic areas of central nervous systems and cardiovascular. The company primarily operates in the US, where it is headquartered in New York City, New York. Forest Labs employed about 5,700 people as of March 31, 2012. The company recorded total net sales of $4,392.5 million during the financial year ended March 2012 (FY2012), an increase of 4.3% over FY2011. The operating profit* of the company was $1,217.3 million in FY2012, a decrease of 6.9% over FY2011. The net profit was $979.1 million in FY2012, a decrease of 6.5% over FY2011. *Earnings before interest and taxes.
Reasons to Purchase:
- Gain understanding of Forest Laboratories, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Forest Laboratories, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Forest Laboratories, Inc.’s business structure, strategy and prospects
For more information, please visit:
Or email us at contact@aarkstore.com or call +919272852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
No comments:
Post a Comment